Drug & intervention

ipilimumab

RxCUI 1094833

Clinical trials97
Recruiting8
Related conditions20
Synonyms1

RxNorm ingredient and formulation relationships

Source-verified product relationships. Every strength, delivery form and RxCUI remains a separate clinical concept.

Loading RxNorm relationships…

Clinical trials

40 shown
First-Line Ipilimumab Plus Nivolumab and Nogapendekin Alfa Inbakicept (N-803) in Patients With Stage IV or Recurrent Non-Small Cell Lung CancerNCT07355205 · 2026-07-07
RECRUITING
DISCERN: Dual Versus Single ICB in PDL-1 Negative NSCLCNCT06364917 · 2025-05-30
RECRUITING
A Study of Oral 7HP349 (Alintegimod) in Combination With Ipilimumab Followed by Nivolumab MonotherapyNCT06362369 · 2024-08-23
RECRUITING
NOvel Immunotherapy Strategies for Advanced Triple Negative Breast Cancer (TNBC) Patients: TONIC-3 TrialNCT06342037 · 2024-06-12
RECRUITING
Safety and Efficacy of NEO212 in Patients With Astrocytoma IDH-mutant, Glioblastoma IDH-wildtype or Brain MetastasisNCT06047379 · 2023-11-01
RECRUITING
Study of Zanzalintinib in Combination With Immuno-Oncology or Other Agents in Participants With Solid TumorsNCT05176483 · 2021-12-14
RECRUITING
BrUOG 397: NEO Rad (LOW): Neoadjuvant Low Dose Stereotactic Body Radiotherapy, Ipilimumab and NivolumabNCT04933903 · 2021-10-05
RECRUITING
Pre-operative Trial for Breast Cancer With Nivolumab in Combination With Novel IONCT03815890 · 2019-10-04
RECRUITING
Concurrent Immunotherapy and Systemic Therapy With Stereotactic Body Radiation Therapy (SBRT) for Stage IV Cancers (COINSSS IV)NCT07770100 · 2026-10-01
NOT_YET_RECRUITING
A Study to Evaluate Two Dosing Regimens of Subcutaneous Nivolumab in Combination With Intravenous Ipilimumab and Chemotherapy in Participants With Previously Untreated Metastatic or Recurrent Non-Small Cell Lung Cancer (NSCLC)NCT06946797 · 2025-09-19
ACTIVE_NOT_RECRUITING
Neoadjuvant Lu-PSMA Radioligand Therapy and Ipilimumab in Men With Very High-risk Prostate CancerNCT06388369 · 2025-08-25
TERMINATED
MEDI5752 in Combination With Carboplatin Plus Pemetrexed in Unresectable Pleural MesotheliomaNCT06097728 · 2023-11-09
ACTIVE_NOT_RECRUITING
Immune Profile Selection By Fraction of ctDNA in Patients With Advanced NSCLC Treated With ImmunotherapyNCT05715229 · 2023-09-29
TERMINATED
Anti-PD-1 Re-challenge After Immune Priming by Ipilimumab and Immune Boosting by Radiotherapy in Advanced NSCLCNCT05401786 · 2023-01-03
ACTIVE_NOT_RECRUITING
A Study to Assess BMS-986207 in Combination With Nivolumab and Ipilimumab as First-line Treatment for Participants With Stage IV Non-Small Cell Lung CancerNCT05005273 · 2022-10-03
COMPLETED
EVOLUTION: 177Lu-PSMA Therapy Versus 177Lu-PSMA in Combination With Ipilimumab and Nivolumab for Men With mCRPCNCT05150236 · 2022-04-29
UNKNOWN
A Randomized Pilot Study of Evolocumab Plus Nivolumab/Ipilimumab in Treatment-Naïve Patients With Metastatic NSCLCNCT05144529 · 2022-03-22
TERMINATED
Study of Nivolumab-Ipilimumab and cfDNA in Lung CancerNCT04966676 · 2022-01-24
TERMINATED
A Study of Immunotherapy Drugs Nivolumab and Ipilimumab in Patients w/Resectable Malignant Peritoneal MesotheliomaNCT05041062 · 2021-12-01
COMPLETED
Nivolumab and Ipilimumab Plus Chemotherapy for Patients With Stage IV Lung Cancer With Brain MetastasesNCT05012254 · 2021-11-18
ACTIVE_NOT_RECRUITING
A Study of Chemoimmunotherapy for the Treatment of Men With Neuroendocrine or Aggressive Variant Metastatic Prostate CancerNCT04709276 · 2021-06-07
ACTIVE_NOT_RECRUITING
A Study Evaluating Safety and Therapeutic Activity of ANV419 in Patients with Advanced Cancer.NCT04855929 · 2021-05-25
COMPLETED
Platform Trial of Novel Regimens Versus Standard of Care (SoC) in Participants With Non-small Cell Lung Cancer (NSCLC) - Sub-study 2NCT06790303 · 2021-03-04
TERMINATED
Immune Checkpoint Inhibition With Lurbinectedin Relapsed/Recurrent SCLCNCT04610658 · 2020-11-23
TERMINATED
Neoadjuvant Immunotherapy in Brain MetastasesNCT04434560 · 2020-11-04
TERMINATED
The Rome Trial From Histology to Target: the Road to Personalize Target Therapy and ImmunotherapyNCT04591431 · 2020-10-07
UNKNOWN
Safety and Efficacy of Combination Osimertinib and Ipilimumab in Patients w EGFR Mutated NSCLCNCT04141644 · 2020-08-20
ACTIVE_NOT_RECRUITING
Microbiome Immunotherapy Toxicity and Response EvaluationNCT04107168 · 2020-07-08
UNKNOWN
A Study Evaluating the Drug Levels of Iplimumab Given Under the Skin Alone and in Combination With Nivolumab in Multiple Tumor TypesNCT04311710 · 2020-06-25
TERMINATED
PROCLAIM: CX-072-002: Study of PD-L1 Probody Therapeutic CX-072 in Combination With Other Anticancer Therapy in Adults With Solid TumorsNCT03993379 · 2019-11-20
TERMINATED
Peri-Operative Immune Checkpoint Inhibition and Cryoablation in Women With Triple-negative Breast CancerNCT03546686 · 2019-11-12
ACTIVE_NOT_RECRUITING
Nivolumab and Ipilimumab in Combination With Immunogenic Chemotherapy for Patients With Advanced NSCLCNCT04043195 · 2019-08-14
ACTIVE_NOT_RECRUITING
Evaluate the Clinical Benefit of a Post-operative Treatment Associating Radiotherapy + Nivolumab + Ipilimumab Versus Radiotherapy + Capecitabine for Triple Negative Breast Cancer Patients With Residual DiseaseNCT03818685 · 2019-07-02
UNKNOWN
Vopratelimab and a CTLA-4 Inhibitor in PD-1/PD-L1 Inhibitor Experienced Subjects With NSCLC or Urothelial CancerNCT03989362 · 2019-06-06
COMPLETED
Study of Autologous Tumor Infiltrating Lymphocytes in Patients With Solid TumorsNCT03645928 · 2019-05-07
TERMINATED
Phase 1/2 Trial of Gavo-cel (TC-210) in Patients With Advanced Mesothelin-Expressing CancerNCT03907852 · 2019-04-15
ACTIVE_NOT_RECRUITING
Nivolumab, Ipilimumab, and Bicalutamide in Human Epidermal Growth Factor (HER) 2 Negative Breast Cancer PatientsNCT03650894 · 2019-04-03
ACTIVE_NOT_RECRUITING
NIMBUS: Nivolumab Plus Ipilimumab in Metastatic Hypermutated HER2-negative Breast CancerNCT03789110 · 2019-03-08
ACTIVE_NOT_RECRUITING
Platform Trial of Novel Regimens Versus Standard of Care (SoC) in Participants With Non-small Cell Lung Cancer (NSCLC)NCT03739710 · 2019-01-24
COMPLETED
Nivolumab +/- Ipilimumab in Patients With Advanced, Refractory Pulmonary or Gastroenteropancreatic Poorly Differentiated Neuroendocrine Tumors (NECs)NCT03591731 · 2019-01-02
COMPLETED

Drug identity and terminology: RxNorm. Trial relationships: ClinicalTrials.gov.